53Biologics has been featured in the latest edition of APTE Technonews (Issue 91), the magazine of the Spanish Association of Science and Technology Parks. The article highlights our contribution to innovation in RNA enzyme manufacturing, a key technology supporting mRNA vaccines, gene therapies, and next-generation RNA-based treatments.
The Challenge of RNA Enzyme Manufacturing
RNA-based therapeutics rely on high-performance enzymes such as RNA polymerase, which is essential for accurate RNA synthesis. However, producing these enzymes at industrial scale presents significant challenges related to purity, catalytic activity, and scalability. Optimizing expression, purification, and formulation conditions is critical for achieving consistent performance and supporting regulatory requirements.
53Biologics: A Partner in RNA Innovation
As a CDMO specialized in biologics production from DNA to proteins, 53Biologics has developed a flexible and scalable approach to RNA enzyme manufacturing. Our approach is designed to improve process flexibility, minimize cross-contamination risks, and enhance production efficiency.
Our facilities support multiple production scales, from 500 L non-GMP to 200 L and 2,000 L GMP batches. This range allows us to adapt manufacturing strategies to different project stages and regulatory pathways, supporting the transition from preclinical development to GMP manufacturing.
Driving the Future of RNA-Based Therapies
Ongoing R&D at 53Biologics focuses on improving enzyme stability, catalytic efficiency, and formulation to expand their potential use in RNA-based therapies, vaccines, and gene-editing tools. This work also complements our participation in the OligoFastX project, which is focused on developing RNA-based therapies for rare diseases.
By combining experience in biologics production with flexible manufacturing capabilities, 53Biologics continues to support the development and manufacturing of technologies that can advance RNA-based therapeutics.
Read the full article in APTE Technonews (page 44): APTE Technonews – Issue 91
About Us
53Biologics is a Spanish CDMO specialized in decoding biologics production, from DNA to proteins. The company provides services from preclinical development to GMP manufacturing, supporting clients in advancing their biological products toward the market.
For more information or to speak with one of our experts, fill out our contact form or email us at info@53biologics.com.